IL122305A0 - Tace polypeptide its production and its use - Google Patents

Tace polypeptide its production and its use

Info

Publication number
IL122305A0
IL122305A0 IL12230596A IL12230596A IL122305A0 IL 122305 A0 IL122305 A0 IL 122305A0 IL 12230596 A IL12230596 A IL 12230596A IL 12230596 A IL12230596 A IL 12230596A IL 122305 A0 IL122305 A0 IL 122305A0
Authority
IL
Israel
Prior art keywords
protease
production
isolated
purified
tace polypeptide
Prior art date
Application number
IL12230596A
Other languages
English (en)
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,345 external-priority patent/US5830742A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL122305A0 publication Critical patent/IL122305A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
IL12230596A 1995-06-08 1996-06-03 Tace polypeptide its production and its use IL122305A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48245895A 1995-06-08 1995-06-08
US50461495A 1995-07-20 1995-07-20
US08/655,345 US5830742A (en) 1995-06-08 1996-05-23 TNF-α converting enzyme
PCT/US1996/008407 WO1996041624A1 (en) 1995-06-08 1996-06-03 TNF-α CONVERTING ENZYME

Publications (1)

Publication Number Publication Date
IL122305A0 true IL122305A0 (en) 1998-04-05

Family

ID=27413615

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12230596A IL122305A0 (en) 1995-06-08 1996-06-03 Tace polypeptide its production and its use

Country Status (13)

Country Link
EP (1) EP0830130B9 (ja)
JP (1) JP4326022B2 (ja)
AT (1) ATE274346T1 (ja)
AU (1) AU712759C (ja)
CA (1) CA2222650C (ja)
DE (1) DE69633231T2 (ja)
DK (1) DK0830130T3 (ja)
ES (1) ES2227598T3 (ja)
IL (1) IL122305A0 (ja)
NO (1) NO323623B1 (ja)
NZ (2) NZ312285A (ja)
PT (1) PT830130E (ja)
WO (1) WO1996041624A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en) 1996-03-01 2001-07-03 The Procter & Gamble Company Disintegrin metalloprotease and its use
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase
JP2000500660A (ja) * 1996-07-12 2000-01-25 シェーリング コーポレイション 哺乳動物ＴＮＦ―αコンベルターゼ
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
AU6241698A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
HUP0100780A2 (hu) * 1997-02-25 2001-06-28 Case Western Reserve University Új dezintegrin metalloproteáz, mutánsai, fragmentumai és hasonlók alkalmazása
US6551857B2 (en) 1997-04-04 2003-04-22 Elm Technology Corporation Three dimensional structure integrated circuits
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
CN1342200A (zh) * 1998-02-04 2002-03-27 免疫检查公司 晶体TNF－α－转换酶及其应用
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
WO2005030798A2 (en) 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
EP2061802A1 (en) * 2006-08-28 2009-05-27 Ares Trading S.A. Process for the purification of fc-fusion proteins
FI2061803T4 (fi) * 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
EP2670775A1 (en) 2011-02-01 2013-12-11 Cancer Research Technology Limited Anti-tace antibody molecules and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0491878T3 (da) * 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
DE69033457T2 (de) * 1989-08-16 2000-09-14 Chiron Corp Prohormonspaltungsplatzblockierungsantikörper
DE59106996D1 (de) * 1990-06-22 1996-01-11 Jens Luedemann Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände.
AU8337291A (en) * 1990-08-06 1992-03-02 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
CA2139127A1 (en) * 1992-06-25 1994-01-06 Chiron Corporation Compositions for the inhibition of protein hormone formation and uses thereof
WO1995024501A1 (en) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase

Also Published As

Publication number Publication date
DE69633231D1 (de) 2004-09-30
AU712759C (en) 2001-08-09
PT830130E (pt) 2004-11-30
DK0830130T3 (da) 2004-12-20
WO1996041624A1 (en) 1996-12-27
ATE274346T1 (de) 2004-09-15
NO975438D0 (no) 1997-11-26
AU6378196A (en) 1997-01-09
AU712759B2 (en) 1999-11-18
CA2222650A1 (en) 1996-12-27
EP0830130B9 (en) 2004-12-29
NZ510390A (en) 2002-11-26
EP0830130A1 (en) 1998-03-25
CA2222650C (en) 2009-10-13
NZ312285A (en) 2001-04-27
JP4326022B2 (ja) 2009-09-02
JP2002515020A (ja) 2002-05-21
NO323623B1 (no) 2007-06-18
ES2227598T3 (es) 2005-04-01
MX9709744A (es) 1998-07-31
EP0830130A4 (en) 2000-03-29
EP0830130B1 (en) 2004-08-25
NO975438L (no) 1998-02-06
DE69633231T2 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
IL122305A0 (en) Tace polypeptide its production and its use
DE69033699T2 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
MX9804262A (es) Inhibidores derivados de d-aminoacidos de proteasas de cisteina y serina.
EP1160327A3 (en) Novel proteolytic enzymes and their use in detergents
CA2058935A1 (en) Pharmaceutical compositions and method for treatment using alzheimer's amyloid peptides
MY119155A (en) New peptide derivatives
HUP9902698A2 (hu) Humán bikunin
MX9706069A (es) Nuevos inhibidores de la trombina.
CA2215695A1 (en) .beta.-sheet mimetics and use thereof as protease inhibitors
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
ATE63750T1 (de) Peptid, dessen herstellung und benutzung.
ES2171563T3 (es) Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
DE69332904D1 (de) Hemmung von hiv-infektion
BR9608978A (pt) Inibidor de protease de serina derivado de imidazo [1,5a] piridina composição farmacêutica e utilização do inibidor de protease
FR2642426B1 (fr) Compose d'organogermanium, procedes pour leur fabrication et agent inhibiteur des enzymes de degradation des peptides opioides
FR2837836B1 (fr) UTILISATION DE LA PROTEINE Maba (FABG1) DE MYCOBACTERIUM TUBERCULOSIS POUR LA CONCEPTION ET LE CRIBLAGE D'ANTIBIOTIQUES
TH20752EX (th) อนุพันธ์เพพไทด์ชนิดใหม่
MX9605037A (es) Inhibidores de factor xa.

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees